Switching From Compounded to Brand-Name: The September 2026 Transition Guide
The price gap that justified compounding has narrowed dramatically. Here is what the switch actually involves — dosing, cost, and the questions to ask before you start.
The short version
- Two oral GLP-1s are now approved: the Wegovy pill in December 2025 and Foundayo (orforglipron) in April 2026.
- Foundayo self-pay starts at $149/month for the lowest dose; eligible commercially insured patients may pay as little as $25/month with a savings card; Medicare Part D access at $50/month opened July 1, 2026.
- Compounded products generally ran roughly $150 to $300 per month, so the cost argument for compounding is much weaker than it was.
- Do not attempt dose conversion yourself. Approved products have their own titration schedules.
For three years the case for compounded GLP-1s was straightforward arithmetic. Compounded product ran roughly $150 to $300 per month against branded pricing above $1,000. At that spread, a lot of people accepted the tradeoffs. That spread no longer describes the market.
What is actually available now
Two oral GLP-1s have been approved in the last year. Novo Nordisk's oral semaglutide — the Wegovy pill — was approved in December 2025 and launched in January 2026. Eli Lilly's orforglipron, marketed as Foundayo, was approved on April 1, 2026 for adults with obesity, or overweight with at least one weight-related comorbid condition, for use alongside a reduced-calorie diet and increased physical activity.
Foundayo is a once-daily small molecule that can be taken at any time of day without food or water restrictions — the first GLP-1 pill without those constraints. In trials, the highest dose delivered an average of 12.4% weight loss.
Eligible patients with commercial insurance may pay as little as $25 per month with a savings card. Self-pay patients can access Foundayo starting at $149 per month for the lowest dose. Eligible Medicare Part D patients gained access at $50 per month beginning July 1, 2026. Check current terms directly with the manufacturer — savings program details change.
Where to get a prescription
The distribution landscape shifted alongside the approvals. Hims & Hers announced in March 2026 that it would make Novo Nordisk's semaglutide injections and pills available to subscribers, while continuing to offer compounded GLP-1s where a provider determines one is clinically necessary. Ro struck a deal with Eli Lilly in April 2026 to prescribe Foundayo, and also offers semaglutide pills and injections and tirzepatide injections.
Marketplaces like Sesame connect you with clinicians who prescribe brand-name product only — no compounded formulations — which is a cleaner path if brand is what you want.
Providers with brand-name or FDA-approved pathways
Every provider below is a paid partner. Pricing changes frequently — confirm current cost on the provider's own page before you enrol.
Marketplace for cash-pay appointments with clinicians who prescribe FDA-approved brand-name medication only — Rybelsus, the oral Wegovy pill, and Foundayo. No compounded product.
See Sesame Care pricing Paid partner linkSemaglutide injection through a licensed US telehealth network. Injectable only — no oral formulation offered.
See Embody pricing Paid partner linkTelehealth intake with both injectable and oral pathways in the questionnaire flow.
See Care Bare Rx pricing Paid partner linkThe dosing conversation
This is the part to get right, and it is not a do-it-yourself exercise.
Do not assume milligram equivalence
Your compounded dose does not map cleanly onto an approved product's schedule. Different molecule, different formulation, different bioavailability. Orforglipron is not semaglutide and the doses are not interchangeable.
Expect to re-titrate
Approved products have defined titration schedules designed to manage gastrointestinal side effects. Your clinician will decide where to start based on your tolerance history, but plan for a ramp rather than a straight swap at your current dose level.
Bring documentation to the appointment
Your current dose in milligrams, the vial concentration, your full formulation including additives, how long you have been at your current dose, and your side effect history. A clinician making this decision without that information is guessing.
What to know about Foundayo specifically
Orforglipron carries a boxed warning for potential thyroid C-cell tumors, including medullary thyroid carcinoma. It should not be used by people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. The most common adverse effects reported include nausea, constipation, diarrhea, vomiting, indigestion, abdominal pain, headache, and hair loss.
In the trials supporting approval, gastrointestinal adverse events predominated and discontinuations were higher with orforglipron than with placebo. The FDA also required postmarketing studies, including a medullary thyroid carcinoma registry-based case series of at least 15 years duration to monitor incidence over time.
The 12.4% average figure comes from the highest dose in clinical trials. Injectable tirzepatide has produced larger average reductions in its own trial program. If you are currently doing well on injectable therapy, moving to an oral for convenience may involve a tradeoff in expected weight loss. Discuss that openly with your clinician rather than discovering it six months in.
Timing your switch
Two things argue for not waiting. First, the FDA proposed on April 30, 2026 to remove semaglutide, tirzepatide, and liraglutide from the 503B Bulks List, finding no remaining clinical need for outsourcing facilities to compound them. Second, litigation is narrowing the market independently — Novo Nordisk has reported filing 132 suits across 40 states with 44 permanent injunctions won.
An unplanned transition, triggered when your supplier stops filling, is worse than a planned one. Planned means you have an appointment, a prescription, and product in hand before your current supply runs out.
A sequence that works
- Check insurance coverage for approved GLP-1s before assuming you are self-pay
- Check manufacturer savings program eligibility
- Book a clinician appointment while you still have four to six weeks of current supply
- Bring your full dosing and formulation history
- Get the new prescription filled and in hand before your last compounded dose
- Follow the approved product's titration schedule as written, not your old dose level
- Track side effects for the first six weeks and report anything severe
The compounded era solved a real access problem during a real shortage. That problem has largely been solved a different way. For most patients, the approved products are now reachable, and the reasons to stay on a compounded formulation have narrowed to the specific clinical cases the law was always meant to cover.
Sources
- FDA press announcement on the approval of Foundayo (orforglipron), April 1, 2026.
- AJMC, reporting on Foundayo pricing tiers, savings card eligibility, boxed warning, and adverse effects.
- Pharmacy Times, coverage of orforglipron approval, ATTAIN-1 and ATTAIN-2 trial results, and adverse event profile.
- FDA approval letter for NDA 220934, including postmarketing requirement for a medullary thyroid carcinoma registry case series.
- Medscape, reporting on telehealth companies transitioning to brand-name GLP-1 supply, 2026.
- FDA proposed rule on 503B Bulks List status, April 30, 2026.